Pasar al contenido principal

FUNCTION AND MECHANISMS OF TREX2 IN SKIN PATHOGENESIS. A NOVEL STRATEGY FOR THE TREATMENT OF PSORIASIS AND ATOPIC DERMATITIS

PID2020-114477RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Photoswitchable Diazocine Derivative for Adenosine A3 Receptor Activation in Psoriasis

  • López Cano, Marc|||0000-0001-8885-3726
  • Scortichini, Mirko
  • Tosh, Dilip K.
  • Salmaso, Veronica
  • Ko, Tongil|||0000-0002-3070-9243
  • Salort, Glòria
  • Filgaira, Ingrid|||0000-0002-9886-3925
  • Soler, Concepció|||0000-0001-6502-5012
  • Trauner, Dirk|||0000-0002-6782-6056
  • Hernando, Jordi|||0000-0002-1126-4138
  • Jacobson, Kenneth A.|||0000-0001-8104-1493
  • Ciruela, Francisco|||0000-0003-0832-3739
Incorporating photoisomerizable moieties within drugs offers the possibility of rapid and reversible light-dependent switching between active and inactive configurations. Here, we developed a photoswitchable adenosine A3 receptor (A3R) agonist that confers optical control on this G protein-coupled receptor through noninvasive topical skin irradiation in an animal model of psoriasis. This was achieved by covalently bonding an adenosine-5'-methyluronamide moiety to a diazocine photochrome, whose singular photoswitching properties facilitated repeated interconversion between a thermally stable, biologically inactive Z agonist form and a photoinduced, pharmacologically active E configuration. As a result, our photoswitchable agonist allowed the precise modulation of A3R function both in vitro and in vivo, which led to a clear light-controlled pharmacotherapeutic effect on mouse skin lesions. This breakthrough not only demonstrates the potential of diazocine photoswitches for in vivo photopharmacology but also paves the way for the development of new strategies for skin-related diseases that require localized and temporally controlled drug action.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Delivery of a sebum modulator by an engineered skin microbe in mice

  • Knödlseder, Nastassia
  • Fábrega, María José
  • Santos Moreno, Javier
  • Manils, Joan
  • Toloza, Lorena
  • Marín Vilar, Maria
  • Fernández Avilés, Cristina
  • Broadbent, Katrina
  • Maruotti, Julien
  • Lemenager, Hélène
  • Carolis, Carlo
  • Zouboulis, Christos C.
  • Soler Prat, Concepció
  • Lood, Rolf
  • Brüggemann, Holger
  • Güell Cargol, Marc, 1982-
Microorganisms can be equipped with synthetic genetic programs for the production of targeted therapeutic molecules. Cutibacterium acnes is the most abundant commensal of the human skin, making it an attractive chassis to create skin-delivered therapeutics. Here, we report the engineering of this bacterium to produce and secrete the therapeutic molecule neutrophil gelatinase-associated lipocalin, in vivo, for the modulation of cutaneous sebum production., This work was funded by the Office of Naval Research (award N62909-18-1-2155), INNOValora (INNOV21-09-1; SynFlora) given by Universitat Pompeu Fabra and Indústria del Coneixement of the Catalan government (AGAUR; IdC 2019 PROD 00057) and SKINDEV ‘Skin microbial devices’ by European Innovation Council (101098826), all granted to M.G., as well as by research grants PID2020-114477RB-I00 to C.S. and PID2021-126249OA-I00 to J.M. from the MCIN/AEI/10.13039/501100011033. N.K. is funded by a Maria Maetzu–UPF fellowship (AEI–MM-CEX2018-000792-M D.COMAS–Programa estatal de fomento investigación científica y técnica de exceléncia, unidades de exceléncia María de Maeztu 2018) and by the Sociedad Española de Químicos Cosméticos (Beca de la SEQC para la presentación de trabajos en el 33rd IFSCC Congress; KNÖDLSEDER, NASTASSIA). M.J.F. is funded by a Juan de la Cierva Fellowship from the Spanish government (award FJC 2018-037096-I). N.K. also received an EMBO short-term fellowship (fellowship no. 8240). J.S.M. is funded by a Marie Skłodowska-Curie Individual Fellowship (European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie grant agreement 882387), a Juan de la Cierva Incorporación Fellowship (IJC2020-043621-I/MCIN/AEI/10.13039/501100011033 and NextGenerationEU/PRTR from the European Union) and a DCEXS MM Postdoc Project (Unidad de Excelencia María de Maeztu, funded by the AEI, ref. CEX2018-000792-M).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases

  • Llorente, Xavier
  • Esteruelas, Gerard
  • Bonilla, Lorena
  • Agudelo, Mariana Garnica
  • Filgaira, Ingrid
  • Lopez-Ramajo, Daniel
  • Gong, Ruoyi C.
  • Soler, Concepció
  • Espina, Marta
  • García, Maria Luisa
  • Manils, Joan
  • Pujol, Montserrat
  • Sánchez-López, Elena
Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of the most effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotrophic lateral sclerosis (ALS), with anti-proliferative effects potentially beneficial for diseases with excessive cell turnover. However, RLZ possesses low water solubility and high light-sensibility. We present here optimized NLCs loaded with RLZ (RLZ-NLCs) as a potential topical treatment. RLZ-NLCs were prepared by the hot-pressure homogenization method using active essential oils as liquid lipids, and optimized using the design of experiments approach. RLZ-NLCs were developed obtaining optimal properties for dermal application (mean size below 200 nm, negative surface charge and high RLZ entrapment efficacy). In vitro release study demonstrates that RLZ-NLCs allow the successful delivery of RLZ in a sustained manner. Moreover, RLZ-NLCs are not angiogenic and are able to inhibit keratinocyte cell proliferation. Hence, a NLCs delivery system loading RLZ in combination with natural essential oils constitutes a promising strategy against keratinocyte hyperproliferative conditions., This research was funded by the Spanish Ministry of Science and Innovation (PID2021-122187NB-C32 to M.G., PID2020-114477RB-I00 to C.S. and PID2021-126249OA-I00 to J.M. from the MCIN/ AEI /10.13039/501100011033)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Delivery of a sebum modulator by an engineered skin microbe in mice

  • Knödlseder, Nastassia
  • Fábrega, María José
  • Santos Moreno, Javier
  • Manils, Joan
  • Toloza, Lorena
  • Marín Vilar, Maria
  • Fernández Avilés, Cristina
  • Broadbent, Katrina
  • Maruotti, Julien
  • Lemenager, Hélène
  • Carolis, Carlo
  • Zouboulis, Christos C.
  • Soler Prat, Concepció
  • Lood, Rolf
  • Brüggemann, Holger
  • Güell Cargol, Marc, 1982-
Microorganisms can be equipped with synthetic genetic programs for the production of targeted therapeutic molecules. Cutibacterium acnes is the most abundant commensal of the human skin, making it an attractive chassis to create skin-delivered therapeutics. Here, we report the engineering of this bacterium to produce and secrete the therapeutic molecule neutrophil gelatinase-associated lipocalin, in vivo, for the modulation of cutaneous sebum production., This work was funded by the Office of Naval Research (award N62909-18-1-2155), INNOValora (INNOV21-09-1; SynFlora) given by Universitat Pompeu Fabra and Indústria del Coneixement of the Catalan government (AGAUR; IdC 2019 PROD 00057) and SKINDEV ‘Skin microbial devices’ by European Innovation Council (101098826), all granted to M.G., as well as by research grants PID2020-114477RB-I00 to C.S. and PID2021-126249OA-I00 to J.M. from the MCIN/AEI/10.13039/501100011033. N.K. is funded by a Maria Maetzu–UPF fellowship (AEI–MM-CEX2018-000792-M D.COMAS–Programa estatal de fomento investigación científica y técnica de exceléncia, unidades de exceléncia María de Maeztu 2018) and by the Sociedad Española de Químicos Cosméticos (Beca de la SEQC para la presentación de trabajos en el 33rd IFSCC Congress; KNÖDLSEDER, NASTASSIA). M.J.F. is funded by a Juan de la Cierva Fellowship from the Spanish government (award FJC 2018-037096-I). N.K. also received an EMBO short-term fellowship (fellowship no. 8240). J.S.M. is funded by a Marie Skłodowska-Curie Individual Fellowship (European Union’s Horizon 2020 Research and Innovation Program under Marie Skłodowska-Curie grant agreement 882387), a Juan de la Cierva Incorporación Fellowship (IJC2020-043621-I/MCIN/AEI/10.13039/501100011033 and NextGenerationEU/PRTR from the European Union) and a DCEXS MM Postdoc Project (Unidad de Excelencia María de Maeztu, funded by the AEI, ref. CEX2018-000792-M).